$3.03
-0.02 (-0.66%)
Open$3.00
Previous Close$3.05
Day High$3.07
Day Low$2.95
52W High$3.19
52W Low$1.65
Volume—
Avg Volume1.28M
Market Cap249.58M
P/E Ratio13.17
EPS$0.23
SectorBiotechnology
Analyst Ratings
Strong Buy
5 analysts
Price Target
+930.0% upside
Current
$3.03
$3.03
Target
$31.21
$31.21
$17.92
$31.21 avg
$31.70
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 54.95M | 53.12M | 361.03M |
| Net Income | -6,881,972 | -5,987,215 | 15.50M |
| Profit Margin | -12.5% | -11.9% | 4.3% |
| EBITDA | -4,206,104 | -3,862,541 | 29.24M |
| Free Cash Flow | — | — | 6.36M |
| Rev Growth | +3.5% | +3.5% | +17.6% |
| Debt/Equity | — | — | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.55 | -0.16% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $456.60 | -1.24% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $169.42 | +1.10% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $531.97 | -1.08% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $951.08 | -0.14% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $159.73 | -3.22% | 7.7 | 20.98B |